Refractory somatotroph adenomas
- PMID: 37316636
- DOI: 10.1007/s11102-023-01324-5
Refractory somatotroph adenomas
Abstract
Somatotroph adenomas are usually controlled with standard therapy, which can include surgery, medical treatment and radiotherapy. Some tumors have a more aggressive behavior and are refractory to standard therapy. In this review, we summarize the phenotype of these tumors and the current options for their management.
Keywords: Acromegaly; Aggressive adenomas; Pasireotide; Pegvisomant; Somatostatin receptor ligands.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.Neuroendocrinology. 2017;105(1):44-53. doi: 10.1159/000448429. Epub 2016 Jul 25. Neuroendocrinology. 2017. PMID: 27455094 Free PMC article.
-
Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.Eur J Endocrinol. 2015 Jun;172(6):707-13. doi: 10.1530/EJE-14-1117. Epub 2015 Mar 19. Eur J Endocrinol. 2015. PMID: 25792375
-
Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.Pituitary. 2006;9(3):221-9. doi: 10.1007/s11102-006-0267-0. Pituitary. 2006. PMID: 17036195 Review.
-
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.Eur J Endocrinol. 2021 Feb;184(2):217-229. doi: 10.1530/EJE-20-0767. Eur J Endocrinol. 2021. PMID: 33136550
-
Management of endocrine disease: GH excess: diagnosis and medical therapy.Eur J Endocrinol. 2013 Nov 29;170(1):R31-41. doi: 10.1530/EJE-13-0532. Print 2014 Jan. Eur J Endocrinol. 2013. PMID: 24144967 Review.
Cited by
-
Treatment-resistant Cushing disease and acromegaly in a young woman: A case of functional pituitary macroadenoma.Radiol Case Rep. 2025 Jan 25;20(4):2013-2019. doi: 10.1016/j.radcr.2025.01.010. eCollection 2025 Apr. Radiol Case Rep. 2025. PMID: 39926265 Free PMC article.
-
Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.Int J Mol Sci. 2023 Sep 12;24(18):14002. doi: 10.3390/ijms241814002. Int J Mol Sci. 2023. PMID: 37762304 Free PMC article. Review.
-
Lysine Methyltransferase 5A Promotes the Progression of Growth Hormone Pituitary Neuroendocrine Tumors through the Wnt/β-Catenin Signaling Pathway.Neuroendocrinology. 2024;114(6):589-601. doi: 10.1159/000538560. Epub 2024 Apr 2. Neuroendocrinology. 2024. PMID: 38565081 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources